NCT00101738

Freedom Study: Myfortic in Kidney Transplant Patients

Study Contact:

Study Phase:

PHASE3

Recruitment Status:

COMPLETED

NCT ID:

NCT00101738

Principal Investigator:

Study Type:

INTERVENTIONAL

Official Title:

Study to Investigate the Clinical Outcomes of Different Regimens of Myfortic® in De Novo Kidney Tx Pts Using Simulect® and Neoral® With or Without Steroids

Summary

The primary objective of the study is to evaluate that 3 immunosuppressant regimens will have comparable kidney function results in kidney transplant patients.

Eligibility

Inclusion Criteria:

* Males and females aged 18 to 75 years.
* Recipients of first, heart-beating cadaveric, living unrelated or living related non-HLA identical donor kidney transplant, treated with Simulect® and Neoral® as primary immunosuppression.

Exclusion Criteria:

* Second or subsequent kidney transplant or multi-organ recipients (e.g. kidney and pancreas) or previous transplant with any other organ.
* Kidneys from non-heart beating donors or HLA identical living related donors.
* ABO incompatibility against the donor.

Disease(s) and\or Condition(s)

Kidney Transplantation

Primary Purpose

TREATMENT

Intervention/Treatment

- Type: DRUG
- Name: Myfortic
- Description:
- Arm Group Labels:

Sponsor

Novartis Pharmaceuticals